The Centers for Disease Control and Prevention today released updated guidance for clinicians treating COVID-19 in patients who received the Pfizer COVID-19 antiviral pill Paxlovid. 

“There is currently no evidence that additional treatment is needed with Paxlovid or other anti-SARS-CoV-2 therapies in cases where COVID-19 rebound is suspected,” CDC said, noting that a brief return of symptoms may be part of the natural history of SARS-CoV-2 infection in some individuals, “independent of treatment with Paxlovid and regardless of vaccination status.”

CDC continues to recommend Paxlovid to treat mild to moderate COVID-19 in patients at high risk for progressing to severe disease and isolating patients when COVID-19 rebounds to manage transmission risk.

Headline
The Department of Health and Human Services June 30 announced it will terminate emergency use authorization declarations for certain drugs and medical devices…
Headline
The Centers for Disease Control and Prevention Feb. 19 released a report on the low use of COVID-19 antiviral drugs among individuals age 65 and older, a…
Headline
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…
Headline
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…
Headline
 The Food and Drug Administration July 10 approved Moderna’s Spikevax COVID-19 vaccine for children under 12 with at least one underlying condition that…
Headline
Department of Health and Human Services Secretary Robert F. Kennedy Jr. May 27 announced in a post on X that the Centers for Disease Control and Prevention…